NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 193 filers reported holding NEKTAR THERAPEUTICS in Q1 2023. The put-call ratio across all filers is 0.02 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,243,000 | -39.9% | 550,000 | 0.0% | 0.13% | -40.1% |
| Q3 2022 | $2,068,000 | -1.1% | 550,000 | 0.0% | 0.22% | -8.4% |
| Q2 2022 | $2,090,000 | -36.8% | 550,000 | -10.4% | 0.24% | -27.3% |
| Q1 2022 | $3,309,000 | -75.1% | 613,884 | -35.4% | 0.33% | -63.1% |
| Q4 2021 | $13,300,000 | -22.0% | 950,000 | 0.0% | 0.88% | -26.2% |
| Q3 2021 | $17,062,000 | +4.7% | 950,000 | 0.0% | 1.20% | +8.2% |
| Q2 2021 | $16,302,000 | -37.6% | 950,000 | -27.3% | 1.11% | -39.3% |
| Q1 2021 | $26,144,000 | +13.9% | 1,307,196 | -3.2% | 1.82% | -2.6% |
| Q4 2020 | $22,950,000 | +38.3% | 1,350,000 | +35.0% | 1.87% | +26.9% |
| Q3 2020 | $16,590,000 | -9.3% | 1,000,000 | +26.6% | 1.48% | -25.4% |
| Q2 2020 | $18,296,000 | -4.7% | 790,000 | -26.5% | 1.98% | -26.5% |
| Q1 2020 | $19,189,000 | -19.2% | 1,075,000 | -2.3% | 2.69% | +3.3% |
| Q4 2019 | $23,744,000 | +8.6% | 1,100,000 | -8.3% | 2.60% | -5.0% |
| Q3 2019 | $21,858,000 | -15.3% | 1,200,000 | +65.5% | 2.74% | -3.6% |
| Q2 2019 | $25,796,000 | +4.5% | 725,000 | -1.3% | 2.84% | -1.6% |
| Q1 2019 | $24,677,000 | +45.8% | 734,445 | +42.6% | 2.89% | +49.1% |
| Q4 2018 | $16,928,000 | -9.1% | 515,000 | +68.6% | 1.94% | +3.8% |
| Q3 2018 | $18,617,000 | -38.3% | 305,393 | -50.6% | 1.86% | -39.6% |
| Q2 2018 | $30,160,000 | +36.8% | 617,652 | +197.7% | 3.09% | +13.6% |
| Q1 2018 | $22,044,000 | +4.4% | 207,458 | -41.3% | 2.72% | -4.8% |
| Q4 2017 | $21,111,000 | +1.5% | 353,503 | -59.2% | 2.85% | +7.5% |
| Q3 2017 | $20,789,000 | +33.8% | 866,194 | +9.0% | 2.65% | +18.9% |
| Q2 2017 | $15,542,000 | +40.9% | 795,000 | +69.1% | 2.23% | +27.8% |
| Q1 2017 | $11,031,000 | +119.3% | 470,000 | +14.6% | 1.75% | +81.2% |
| Q4 2016 | $5,031,000 | -99.9% | 410,000 | +5.1% | 0.96% | -9.4% |
| Q3 2016 | $6,700,200,000 | +100082.4% | 390,000 | -17.0% | 1.06% | -10.4% |
| Q2 2016 | $6,688,000 | -7.4% | 470,000 | -10.5% | 1.19% | -17.1% |
| Q1 2016 | $7,219,000 | -26.3% | 525,000 | -9.6% | 1.43% | -3.2% |
| Q4 2015 | $9,790,000 | +29.8% | 581,000 | -15.6% | 1.48% | +23.1% |
| Q3 2015 | $7,540,000 | -35.7% | 688,000 | -26.6% | 1.20% | -14.6% |
| Q2 2015 | $11,722,000 | +6.9% | 937,000 | -6.0% | 1.41% | -23.9% |
| Q1 2015 | $10,963,000 | +197.2% | 996,600 | +318.7% | 1.85% | +73.0% |
| Q4 2014 | $3,689,000 | -39.8% | 238,000 | -53.1% | 1.07% | -40.4% |
| Q3 2014 | $6,132,000 | +84.0% | 508,000 | +95.4% | 1.80% | +81.5% |
| Q2 2014 | $3,333,000 | +51.3% | 260,000 | +43.0% | 0.99% | +49.6% |
| Q1 2014 | $2,203,000 | +2.1% | 181,797 | -4.3% | 0.66% | -21.7% |
| Q4 2013 | $2,157,000 | – | 190,000 | – | 0.84% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |